FDA approval adds Belotero Intense (+) Lidocaine to the lip-augmentation lineup.
The FDA approved Belotero Intense (+) Lidocaine on July 9, 2026 for submucosal and/or subcutaneous implantation for lip augmentation in adults over 21. Approval confirms an authorized indication and labeling pathway, not that one filler is best for every lip shape, anatomy or risk profile.
Reviewed for the Dagan Edit
Share quietly
Editorial material study representing hyaluronic-acid lip filler selection and tissue-plane planning; not an actual patient result
The report, in context
What this development means—and what it does not.
The FDA approved Belotero Intense (+) Lidocaine on July 9, 2026 for submucosal and/or subcutaneous implantation for lip augmentation in adults over 21. Approval confirms an authorized indication and labeling pathway, not that one filler is best for every lip shape, anatomy or risk profile.
Inclusion is not an endorsement; treatment suitability, product safety and postoperative care require individualized guidance from a qualified clinician.
Madison Avenue · New York City
Bring the question into a clinical conversation.
A consultation connects general educational context to an individual examination, reasonable options, limitations, and recovery.
